GLP-1 and Kidney Disease: The FLOW Trial Evidence

GLP-1s get discussed almost entirely in terms of weight and blood sugar, but one of the more consequential recent trials in this drug class wasn't about either — it was about the kidneys. The FLOW trial tested whether semaglutide could slow chronic kidney disease progression in people with type 2 diabetes, and it succeeded clearly enough to become a new item on the FDA label.

The trial

FLOW enrolled adults with type 2 diabetes and chronic kidney disease and randomized them to semaglutide or placebo, tracking a composite primary outcome: major kidney disease events (a sustained large drop in kidney function, the start of dialysis or transplant, or death from kidney causes), cardiovascular death, and death from any cause¹. This was a large, purpose-built outcomes trial, not a side analysis of a weight-loss study.

The results

The primary outcome — the composite of kidney events and cardiovascular death — occurred in 331 people on semaglutide versus 410 on placebo, a 24% relative risk reduction (hazard ratio 0.76, P=0.0003)¹. Looking specifically at the kidney-only components of that composite, the reduction was similar: a hazard ratio of 0.79¹. Semaglutide also reduced cardiovascular death specifically (hazard ratio 0.71), reduced major cardiovascular events overall by 18% (hazard ratio 0.82, P=0.029), and reduced all-cause mortality by 20% (hazard ratio 0.80, P=0.01)¹. On a more granular kidney-function measure, the average annual rate of eGFR decline — how fast kidney function drops over time — was 1.16 mL/min/1.73m² per year slower in the semaglutide group, a statistically significant difference (P<0.001)¹. Put simply: this wasn't a marginal, borderline-significant result. Every major outcome the trial measured moved in the same direction, and several were highly statistically significant.

Why this changed the label, not just the research literature

Trial results this strong on a hard clinical endpoint — not a surrogate marker, but actual kidney failure, dialysis, transplant, and death — are exactly what regulatory agencies use to expand a drug's approved indication. Ozempic's current FDA label now includes an indication "to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease"² — language drawn directly from what FLOW measured. That's a meaningfully different regulatory status than an interesting research finding that hasn't yet reached the label; it means a prescriber can write Ozempic specifically for this purpose, and insurance coverage discussions can point to an on-label indication rather than an off-label use.

What this doesn't establish

FLOW enrolled people who already had type 2 diabetes and chronic kidney disease — it does not tell us whether semaglutide prevents kidney disease from developing in someone without diabetes or existing kidney impairment, and it doesn't extend this specific finding to other GLP-1s that haven't run the equivalent trial. If kidney health is a significant factor in your own medical picture, that's a reason to ask your prescriber directly whether this specific evidence and label indication apply to your situation, not to assume every GLP-1 carries the same benefit.

Where this fits alongside the drug's other effects

Kidney protection joins a growing list of indications beyond weight loss that semaglutide has picked up as more purpose-built outcomes trials complete — cardiovascular risk reduction and, for Wegovy specifically, liver disease (MASH) are others; see Wegovy vs Zepbound: what's actually different for how the two major obesity brands' approved uses have diverged. None of these additional indications change the core interaction and side-effect profile you should discuss with a prescriber before starting — see GLP-1 drug interactions: what to tell your prescriber and GLP-1 boxed warnings: what the label actually says for that full picture.

Where this fits your provider decision

If chronic kidney disease is part of your medical history alongside type 2 diabetes, ask whether your prescriber is aware of this specific indication and whether it changes how they're framing your treatment. Compare pricing across verified semaglutide programs on our semaglutide price board, and see how we weigh medical substance in our Value Score methodology.

This piece sits in our research index alongside every other sourced explainer we publish — the trials, the compounding rules and the pricing mechanics, grouped by the question each one answers.